{"result": "(\"entity\"<|>UPTODATE INC.<|>ORGANIZATION<|>UpToDate Inc. is a medical information provider that offers literature reviews and clinical guidelines for healthcare professionals.)\n##\n(\"entity\"<|>YOUNG WF, JR.<|>PERSON<|>Young WF, Jr. is a medical professional who has contributed to the literature on pheochromocytoma and paraganglioma, including clinical presentations and treatment options.)\n##\n(\"entity\"<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>ORGANIZATION<|>Harrison's Principles of Internal Medicine is a comprehensive medical textbook that includes information on various medical conditions, including pheochromocytoma.)\n##\n(\"entity\"<|>WALTHAM<|>GEO<|>Waltham is a city in Massachusetts, USA, where UpToDate Inc. is located.)\n##\n(\"entity\"<|>MÉXICO DF<|>GEO<|>Mexico City, known as México DF, is the capital of Mexico and is referenced in the context of medical literature.)\n##\n(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Pheochromocytoma is a type of tumor that secretes catecholamines and is discussed in the context of clinical guidelines and treatment.)\n##\n(\"entity\"<|>PARAGANGLIOMA<|>EVENT<|>Paraganglioma is a related tumor type that is often discussed alongside pheochromocytoma in medical literature.)\n##\n(\"relationship\"<|>YOUNG WF, JR.<|>UPTODATE INC.<|>Young WF, Jr. has contributed to the clinical guidelines published by UpToDate Inc. regarding pheochromocytoma and paraganglioma<|>8)\n##\n(\"relationship\"<|>YOUNG WF, JR.<|>HARRISON PRINCIPIOS DE MEDICINA INTERNA<|>Young WF, Jr. is referenced in Harrison's Principles of Internal Medicine for his work on pheochromocytoma<|>7)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>PARAGANGLIOMA<|>Pheochromocytoma and paraganglioma are often discussed together in medical literature due to their related nature<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ad MH, et al. Pheochromocytoma and paraganglioma:             Referencias:\n           an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.                                         • Díaz Pérez JA, Crespo Hernández I. Feocromocitoma y paraganglioma. Manual de Endocrinología y Nutrición. Disponible en:\n         • Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios            https://manual.seen.es (última modificación: 24 de noviembre de 2015).\n           de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2329-35.                                            • Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma:\n         • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook                     an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.\n           of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.                                                                 • Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios\n         • Young WF, Jr. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. Waltham, MA: UpToDate Inc. https://www.              de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2329-35.\n           uptodate.com. Literature review current through: Apr. 2019.                                                                         • Young WF, Jr. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n         • Young WF, Jr, Kebebew E. Treatment of pheochromocytoma in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.          uptodate.com. Literature review current through: Apr. 2019.\n           com. Literature review current through: Apr. 2019.                                                                                  • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n                                                                                                                                                 of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n                                                                                                                                               • Young WF, Jr, Kebebew E. Treatment of pheochromocytoma in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.\n                                                                                                                                                 com. Literature review current through: Apr. 2019.\n     27  En   relación con el manejo preoperatorio de los feocromocitomas, indique cuál\n         de las siguientes afirmaciones                   es correcta:\n                                                                                                                                           28  Respecto        a los feocromocitomas,                ¿cuál de las siguientes              afirmaciones es cierta?\n         A.  Pacientes normotensos y asintomáticos no precisan preparación farmacológica.\n         B.  La preparación farmacológica debe iniciarse el día anterior a la intervención quirúrgica.                                         A.  El feocromocitoma maligno es frecuente (más del 20% en la mayor parte de las series)\n         C.  El bloqueo betaadrenérgico debe iniciarse una vez que se ha instaurado el bloqueo                                                     en la neoplasia endocrina múltiple tipo 2 (MEN2).\n             alfaadrenérgico.                                                                                                                  B.  El feocromocitoma maligno es frecuente (mas del 20% en la mayor parte de las series)\n         D.  Los bloqueantes de los canales de calcio están contraindicados en el manejo                                                           en las mutaciones de SDHB.\n             preoperatorio de esta patología.                                                                                                  C.  Los antidepresivos tricíclicos pueden producir comúnmente falsos negativos en la\n                                                                                                                                                   medición de las metanefrinas.\n         COMENTARIO                                                                                                                            D.  Las tres respuestas son falsas.\n         Una vez que el tumor secretor de catecolaminas ha sido diagnosticado, su tratamiento de                                               COMENTARIO\n         elección es quirúrgico, pero es necesario realizar una preparación médica adecuada en to-\n         dos los pacientes. El tratamiento preoperatorio incluye siempre un control adecuado de las                                            Aproximadamente, el             10% de los feocromocitomas y hasta un 20-25% de los paragan-\n         crisis hipertensivas y una             adecuada expansión de volumen. El bloqueo                            alfaadrenérgico           gliomas son malignos. Se considera malign\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}